L
Leap Therapeutics D
D
LPTX
0.50520
USD
-0.23
(-31.16%)
مغلق
حجم التداول
88,156
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
20,935,250
الأخبار المقالات
العنوان: Leap Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patientswith colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.